If you are looking for stocks that are well positioned to maintain their recent uptrend, Materion (MTRN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Arq, Inc. (ARQ) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

W.P. Carey's strong Q2 results, strategic asset moves and solid dividend growth highlight its market outperformance in 2025.

LM Funding America, Inc. (LMFA) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.52 per share. This compares to a loss of $1.65 per share a year ago.

Spartan Stores (SPTN) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.59 per share a year ago.

AFC Gamma Inc. (AFCG) came out with quarterly earnings of $0.15 per share, missing the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.56 per share a year ago.

Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call August 14, 2025 8:30 AM ET Company Participants David A. Rosa - President, CEO & Director Ronald W.

I maintain a long-term 'strong buy' on Markel (MKL) for its attractive valuation and resilient, Berkshire-like business model. Recent insurance underperformance is being addressed through sensible reorganization, decentralizing decision-making and focusing on specialty underwriting. Markel's three-engine model—insurance, investments, and ventures—creates a compounding flywheel, with improved underwriting set to accelerate returns.

Lithium is poised to become a red-hot commodity in the basic materials sector, driven by a couple of key macro tailwinds. First and foremost, the new data center buildout across the United States will require a decent amount of lithium to be used in the supercomputers that will train tomorrow's leading artificial intelligence models.

Ideal Power Inc (NASDAQ:IPWR) said on Thursday its first design win customer is close to completing prototype testing for a B-TRAN-enabled solid-state circuit breaker (SSCB) ahead of a planned rollout later this year. “Our first design win customer is nearing completion of their B-TRAN-enabled solid-state circuit breaker (SSCB) prototype testing,” CEO Dan Brdar said in a statement.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has enrolled and dosed the first participant in its Phase 2a clinical trial evaluating intranasal foralumab in patients with Multiple System Atrophy (MSA). The trial is being conducted at Brigham and Women's Hospital in Boston, Massachusetts.

I rate VanEck Alternative Asset Manager ETF a Buy, targeting capital appreciation from the surge in alternative investments entering 401Ks after a recent executive order. The GPZ ETF offers exposure to the top 20 public alternative asset managers, benefiting from a $12.5 trillion retirement market and outpacing the financial sector since launch. The ETF provides diversification across private equity, credit, infrastructure, and real estate, with a low expense ratio and minimal direct competition among ETFs.

Bitcoin enjoyed a long summer in the spotlight, as prices notched new records and regulatory policy proved favorable. Not to be outdone, the Ethereum network made a number of headlines in recent weeks.

Central banks' willingness to buy more precious metals should help buoy prices for both gold and silver. Around the globe, central banks continue to quench their thirst for both, providing investment opportunities in ETFs with exposure to both metals.

CEG beats on Q2 earnings and revenues, secures Meta deal, and advances nuclear and renewable growth plans.

The Zacks Medical products industry sees steady demand, but tariffs & policy headwinds keep growth under pressure in 2025. NVST, BLFS, INFU and MRMD reflect the favorable fundamentals.

Investors need to pay close attention to CADE stock based on the movements in the options market lately.

ABT wins FDA nod for its Tendyne TMVR system, offering a minimally invasive option for patients with severe mitral valve disease.

Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.24 per share a year ago.

Heritage Insurance is pivoting to growth after years of consolidation, boasting improved underwriting and a more diversified geographic footprint beyond Florida. The company relies heavily on reinsurance, which acts as off-balance-sheet leverage, masking the true risk profile and increasing exposure to annual reinsurance market changes. Heritage's growth plans coincide with a softening insurance market, raising concerns about profitability as pricing power declines and catastrophe risks remain elevated.